7
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      MHC class II transactivator CIITA induces cell resistance to Ebola virus and SARS-like coronaviruses

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          The CIITAdel keeps viruses at bay

          A better understanding of cellular mechanisms involved in viral resistance is needed for the next generation of antiviral therapies. Bruchez et al. used a transposon-mediated gene-activation screen to search for previously unreported host restriction factors for Ebola virus (see the Perspective by Wells and Coyne). The authors found that a transcription factor, major histocompatibility complex class II transactivator (CIITA), induces resistance in human cell lines by directing the expression of the p41 isoform of the invariant chain (CD74). CD74 p41 then disrupts cathepsin-mediated Ebola glycoprotein processing, which prevents viral fusion and entry. CD74 p41 can also stymie the endosomal entry of coronaviruses, including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). This work should inform future treatments against cathepsin-dependent viruses such as filoviruses and coronaviruses. Additionally, the screening strategy used may serve as a blueprint for uncovering resistance mechanisms against other dangerous pathogens.

          Science, this issue p. 241 see also p. [Related article:]167

          Abstract

          CIITA and CD74 are host antiviral factors that inhibit Ebola and SARS virus fusion and entry.

          Abstract

          Recent outbreaks of Ebola virus (EBOV) and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have exposed our limited therapeutic options for such diseases and our poor understanding of the cellular mechanisms that block viral infections. Using a transposon-mediated gene-activation screen in human cells, we identify that the major histocompatibility complex (MHC) class II transactivator (CIITA) has antiviral activity against EBOV. CIITA induces resistance by activating expression of the p41 isoform of invariant chain CD74, which inhibits viral entry by blocking cathepsin-mediated processing of the Ebola glycoprotein. We further show that CD74 p41 can block the endosomal entry pathway of coronaviruses, including SARS-CoV-2. These data therefore implicate CIITA and CD74 in host defense against a range of viruses, and they identify an additional function of these proteins beyond their canonical roles in antigen presentation.

          Related collections

          Most cited references45

          • Record: found
          • Abstract: found
          • Article: not found

          SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor

          Summary The recent emergence of the novel, pathogenic SARS-coronavirus 2 (SARS-CoV-2) in China and its rapid national and international spread pose a global health emergency. Cell entry of coronaviruses depends on binding of the viral spike (S) proteins to cellular receptors and on S protein priming by host cell proteases. Unravelling which cellular factors are used by SARS-CoV-2 for entry might provide insights into viral transmission and reveal therapeutic targets. Here, we demonstrate that SARS-CoV-2 uses the SARS-CoV receptor ACE2 for entry and the serine protease TMPRSS2 for S protein priming. A TMPRSS2 inhibitor approved for clinical use blocked entry and might constitute a treatment option. Finally, we show that the sera from convalescent SARS patients cross-neutralized SARS-2-S-driven entry. Our results reveal important commonalities between SARS-CoV-2 and SARS-CoV infection and identify a potential target for antiviral intervention.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Enzymatic assembly of DNA molecules up to several hundred kilobases.

            We describe an isothermal, single-reaction method for assembling multiple overlapping DNA molecules by the concerted action of a 5' exonuclease, a DNA polymerase and a DNA ligase. First we recessed DNA fragments, yielding single-stranded DNA overhangs that specifically annealed, and then covalently joined them. This assembly method can be used to seamlessly construct synthetic and natural genes, genetic pathways and entire genomes, and could be a useful molecular engineering tool.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              The Cancer Cell Line Encyclopedia enables predictive modeling of anticancer drug sensitivity

              The systematic translation of cancer genomic data into knowledge of tumor biology and therapeutic avenues remains challenging. Such efforts should be greatly aided by robust preclinical model systems that reflect the genomic diversity of human cancers and for which detailed genetic and pharmacologic annotation is available 1 . Here we describe the Cancer Cell Line Encyclopedia (CCLE): a compilation of gene expression, chromosomal copy number, and massively parallel sequencing data from 947 human cancer cell lines. When coupled with pharmacologic profiles for 24 anticancer drugs across 479 of the lines, this collection allowed identification of genetic, lineage, and gene expression-based predictors of drug sensitivity. In addition to known predictors, we found that plasma cell lineage correlated with sensitivity to IGF1 receptor inhibitors; AHR expression was associated with MEK inhibitor efficacy in NRAS-mutant lines; and SLFN11 expression predicted sensitivity to topoisomerase inhibitors. Altogether, our results suggest that large, annotated cell line collections may help to enable preclinical stratification schemata for anticancer agents. The generation of genetic predictions of drug response in the preclinical setting and their incorporation into cancer clinical trial design could speed the emergence of “personalized” therapeutic regimens 2 .
                Bookmark

                Author and article information

                Journal
                Science
                Science
                SCIENCE
                science
                Science (New York, N.y.)
                American Association for the Advancement of Science
                0036-8075
                1095-9203
                09 October 2020
                27 August 2020
                : 370
                : 6513
                : 241-247
                Affiliations
                [1 ]Benaroya Research Institute, Seattle, WA 98101, USA.
                [2 ]National Institute of Allergy and Infectious Diseases (NIAID) Integrated Research Facility, Frederick, MD 21702, USA.
                [3 ]Massachusetts General Hospital, Boston, MA 02114, USA.
                [4 ]Department of Genome Sciences, University of Washington, Seattle, WA 98109, USA.
                [5 ]Boston University School of Medicine, Boston, MA 02118, USA.
                [6 ]National Emerging Infectious Diseases Laboratories, Boston University, Boston, MA 02118, USA.
                [7 ]Merck and Co., Inc, Kenilworth, NJ 07033, USA.
                [8 ]MRIGlobal, Gaithersburg, MD 20878, USA.
                [9 ]Bill and Melinda Gates Foundation, Seattle, WA 98109, USA.
                [10 ]Department of Immunology, University of Washington, Seattle, WA 98109, USA.
                Author notes
                [*]

                These authors contributed equally to this work.

                [†]

                Present address: Department of Pathology, Case Western Reserve University, Cleveland, OH 44106, USA.

                [‡]

                Present address: AbViro LLC, Bethesda, MD 20814, USA.

                [§]

                Present address: Division of Basic Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA.

                [¶]

                Present address: Graduate Program in Molecular Microbiology, Tufts Graduate School of Biomedical Sciences and Department of Molecular Biology and Microbiology, Tufts University, Boston, MA 02155, USA.

                [# ]Corresponding author. Email: alacyhulbert@ 123456benaroyaresearch.org
                Author information
                https://orcid.org/0000-0003-1695-5349
                https://orcid.org/0000-0001-8802-4186
                https://orcid.org/0000-0002-5677-3841
                https://orcid.org/0000-0001-9303-4047
                https://orcid.org/0000-0003-3420-432X
                https://orcid.org/0000-0002-3973-9406
                https://orcid.org/0000-0001-9149-551X
                https://orcid.org/0000-0001-8454-3472
                https://orcid.org/0000-0003-3547-9376
                https://orcid.org/0000-0003-4687-9367
                https://orcid.org/0000-0001-7338-0292
                https://orcid.org/0000-0003-2162-0156
                Article
                abb3753
                10.1126/science.abb3753
                7665841
                32855215
                426ab487-29d6-430a-a376-3b7d690aede8
                Copyright © 2020 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works

                This is an open-access article distributed under the terms of the Creative Commons Attribution license, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

                History
                : 21 February 2020
                : 20 August 2020
                Funding
                Funded by: doi http://dx.doi.org/10.13039/100000060, National Institute of Allergy and Infectious Diseases;
                Award ID: R33AI102266
                Funded by: doi http://dx.doi.org/10.13039/100000060, National Institute of Allergy and Infectious Diseases;
                Award ID: U01AI070330
                Funded by: doi http://dx.doi.org/10.13039/100000060, National Institute of Allergy and Infectious Diseases;
                Award ID: R33AI119341
                Funded by: doi http://dx.doi.org/10.13039/100000060, National Institute of Allergy and Infectious Diseases;
                Award ID: 3U19AI125378 - 04W1
                Categories
                Report
                Reports
                Reports
                Immunology
                Custom metadata
                4
                4
                Seth Scanlon
                Julia Katris

                Uncategorized
                Uncategorized

                Comments

                Comment on this article